Remdesivir for the Treatment of Covid-19 — Final Report
Top Cited Papers
- 5 November 2020
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 383 (19), 1813-1826
- https://doi.org/10.1056/nejmoa2007764
Abstract
Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. A total of 1063 patients underwent randomization. The data and safety monitoring board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who underwent randomization (27.0%). Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 ClinicalTrials.gov number, NCT04280705.)Keywords
Funding Information
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Cancer Institute (HHSN261200800001E, HHSN261201500003I)
- National Institute of Allergy and Infectious Diseases (UM1AI148450, UM1AI148452, UM1AI148573, UM1AI148575, UM1AI148576, UM1AI148684, UM1AI148685, UM1AI148689)
This publication has 14 references indexed in Scilit:
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and ControlJournal of Clinical Medicine, 2020
- Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infectionProceedings of the National Academy of Sciences of the United States of America, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNature Communications, 2020
- Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymeraseAntiviral Research, 2019
- Clinical Development of Therapeutic Agents for Hospitalized Patients With Influenza: Challenges and InnovationsOpen Forum Infectious Diseases, 2019
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading ExoribonucleasemBio, 2018
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaquesProceedings of the National Academy of Sciences of the United States of America, 2013